drug · antibody drug conjugate
trastuzumab deruxtecan
Marketedupdated 6mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.
indications
investigational
NSCLCColorectal Cancer
targets
Receptor tyrosine-protein kinase erbB-2DNA topoisomerase 1
all catalysts(13)
approval · 13
Dec 20, 2019
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 15, 2021
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
May 4, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
May 4, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Aug 5, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Aug 11, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Nov 4, 2022
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Feb 15, 2024
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Apr 5, 2024
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 27, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Jan 27, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Dec 15, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Dec 15, 2025
approval
ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approval
trastuzumab deruxtecan
→
Trials studying trastuzumab deruxtecan
- phase1A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors
- phase3A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- phase2A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
- phase3A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
- phase2Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- phase3DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
- phase2Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- phase2A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
News(10)
- BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer studyThe companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.biopharma_dive · 24d ago
- BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD casesBioNTech has reported modest efficacy and unexpected safety findings in a phase 3 breast cancer trial, leading the company to conclude its HER2-directed candidate may offer limited benefits in the…fiercebiotech · 24d ago
- ESMO: AstraZeneca exec insists phase 3 ADC data ‘robust’ enough for regulators despite PFS missAn AstraZeneca executive was adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug conjugate are “robust” enough to take to regulators, despite the trial fai…fiercebiotech · 26d ago
- STAT+: England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing dealA breast cancer drug from AstraZeneca will now be available in England after a pricing deal was reached, in part a result of the U.S.-U.K. pharma pact.stat · 2mo ago
- WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightThe year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.biopharma_dive · 2mo ago
- Electra aims for nearly $300M IPO; Enhertu's Phase 3 lung cancer successPlus news about Lilly, Cellectis, Tyra, Shennon and QL Biopharm. Electra Therapeutics eyes $297M IPO: The Sanofi-backed biotech hopes to kick off the post-Labor Day IPO train with a nearly $300 mil…endpoints · 2mo ago
- Unlocking cell surface protein research with site-specific labelingApplications in flow cytometry, cell sorting, target validation, and therapeutic discoverybiospace · 2mo ago
- Genentech doubles down on ADC-resistant cancers with $1B DualityBio pactRoche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with the modality. Th…fiercebiotech · 2mo ago
- Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ ZiiheraGastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.biospace · 2mo ago
- AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, EnhertuAstraZeneca on Monday reported successes in two late-stage trials in different forms of lung cancer — one with a two-drug combination of Tagrisso and Orpathys and another with its blockbuster antib…endpoints · 3mo ago
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that